{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:53:23Z","timestamp":1778158403291,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.clon.2016.04.040","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T18:44:06Z","timestamp":1462041846000},"page":"e115-e120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences"],"prefix":"10.1016","volume":"28","author":[{"given":"P.","family":"Ost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.A.","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Van As","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Casamassima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Surgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Miralbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2016.04.040_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib2","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2016.04.040_bib3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib4","first-page":"983","article-title":"Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature","volume":"194","author":"Ploussard","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","article-title":"The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: a systematic review and meta-analysis","volume":"64","author":"Umbehr","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.04.040_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2016.04.040_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer","volume":"82","author":"Jereczek-Fossa","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2016.04.040_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/030089161109700110","article-title":"Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients","volume":"97","author":"Casamassima","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.clon.2016.04.040_bib11","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","article-title":"Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and\/or distant metastases","volume":"52","author":"Schick","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2016.04.040_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clon.2015.03.006","article-title":"Initial UK experience of stereotactic body radiotherapy for extracranial oligometastases: can we change the therapeutic paradigm?","volume":"27","author":"Aitken","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clon.2016.04.040_bib13","series-title":"Common Terminology Criteria for Adverse Events v4.0","author":"National Cancer Institute","year":"2009"},{"key":"10.1016\/j.clon.2016.04.040_bib14","first-page":"299","article-title":"Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years","volume":"67","author":"Suardi","year":"2015","journal-title":"Our Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib15","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2006.10.045","article-title":"The natural history of noncastrate metastatic prostate cancer after radical prostatectomy","volume":"51","author":"Yossepowitch","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00066-014-0763-5","article-title":"Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only","volume":"4","author":"Rischke","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2016.04.040_bib18","first-page":"1270","article-title":"C-Choline PET\/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients","volume":"41","author":"Picchio","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clon.2016.04.040_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-6-44","article-title":"[18F]fluoroethylcholine-PET\/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET\/CT-positive lymph nodes","volume":"6","author":"Wurschmidt","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2016.04.040_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2013.08.021","article-title":"Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy","volume":"109","author":"Van Praet","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2016.04.040_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1186\/s12885-015-1579-0","article-title":"OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer","volume":"15","author":"Supiot","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2016.04.040_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clon.2016.04.040_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","article-title":"MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study","volume":"9","author":"Heesakkers","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2016.04.040_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2013.07.032","article-title":"Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer","volume":"64","author":"Birkhauser","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2016.04.040_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pros.22750","article-title":"Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer","volume":"74","author":"Ost","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.clon.2016.04.040_bib26","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1093\/annonc\/mdt335","article-title":"Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy","volume":"24","author":"Schweizer","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665551630067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665551630067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:43:05Z","timestamp":1760542985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093665551630067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S093665551630067X"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2016.04.040","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2016.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}